Skip to main content
SpringerLink
Log in

EMPA-REG-OUTCOME-Studie

38-prozentige Senkung der kardiovaskulären Mortalität

EMPA REG OUTCOME Study

38 percent reduction in cardiovascular mortality

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117–2128

  2. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UL, Johansen OE (2015) SGLT2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bakris GL, Molitch M (2014) Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care 37:867–875

    Article  PubMed  Google Scholar 

  5. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC (2013) EMPA-TREG MONO trial investigators. Epagiflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase trial. Lancet Diabetes Endocrinol 1:208–219

    Article  CAS  PubMed  Google Scholar 

  6. Rosenstock J, Ferrannini E (2015) Euglycemic diabetic Ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38:1638

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knappschaftskrankenhaus, Klinikum Vest GmbH, Dorstener Str. 151, 45657, Recklinghausen, Deutschland

    I. Vardarli EU M.Sc. &  C. Özcelik

Authors
  1. I. Vardarli EU M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Vardarli EU M.Sc..

Ethics declarations

Interessenkonflikt

I. Vardarli und C. Özcelik geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vardarli, I., Özcelik, C. EMPA-REG-OUTCOME-Studie. Kardiologe 10, 78–80 (2016). https://doi.org/10.1007/s12181-016-0047-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-016-0047-7

Search

Navigation